Top Stories
The company said Livsayis becomes the first and only approved siRNA therapy in generalised myasthenia gravis (gMG).
The companies will combine clinical trial findings with real-world patient data to investigate treatment outcomes, including measures of health beyond weight loss.
The investment was co-led by F-Prime, NEA, RA Capital Management, and Sanofi Ventures with participation from Eli Lilly and other existing investors.
The MIT spinout says six of the world's 20 largest drugmakers have partnered with it to access its biomolecular AI models.
Preliminary Phase III data from the ADEPT programme presented at CTAD come as the company awaits pivotal readouts next year.
Conference News
Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed ORR, median duration of response of 9.2 months and median PFS of 6.7 monthsClinical activit...
FirstWord hosted an expert call this week with Mount Sinai's Jeffrey Weinberg about Phase III ICONIC-PsA data for J&J's Icotyde, and how the oral IL-23 inhibitor could fit into the treatment algorithm for psoriatic arthritis.
Physicians see a niche for Boehringer Ingelheim and Zealand Pharma's survodutide among patients with obesity intolerant to marketed GLP-1 receptor agonists, though they seem doubtful that the glucagon/GLP-1 agonist can challenge established rivals.
New real-world evidence data from AMBAR® describe cognitive outcomes observed over 18 months in patients who underwent therapeutic plasma exchange (TPE) with albumin replacement in a real-world observ...
Drug Development Leaders Share RAS Findings at Global SymposiumFORT MYERS, Fla., Nov. 18, 2026 /PRNewswire/ -- Studies of emerging approaches to targeting RAS mutations, including two first-in-human c...




